Uncategorized
Novel ocular insert maintains lowered IOP in patients with open-angle glaucoma or ocular hypertension
FORT LAUDERDALE, Fla. — A novel bimatoprost insert can provide IOP reduction for up to 13 consecutive months in patients with open-angle glaucoma or ocular hypertension, according to mid-term data of an open-label extension study presented here.IOP was reduced 4 mm Hg to 5 mm Hg in patients included in the study, an extension of a phase 2 clinical trial that looked at efficacy and safety of the novel bimatoprost insert, Kuldev Singh, MD, told colleagues at the American Glaucoma Society meeting, where he delivered the presentation in place of (Read more...)